tbuckley/cabot-search huggingface dataset:
AB0616 Adaptation into spanish of The Hand Mobility in Systemic Sclerosis Test (Hamis) in A Group of Patients with Systemic Sclerosis
Authors: M.M. Mayer, G. Alsina, J.A. Maldonado Cocco, M. Rivero, M.E. Lara, P. Maldonado Alsina, A. Gallacher, M. Khoury, G. Earsman, J.C. Barreira
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hand function in scleroderma patients can be assessed by specific instruments such as the Cochin scale and the Scleroderma Health assessment questionnaire (SHAQ), both self administrated. Sanqvist and Eklun designed the Hand Mobility in Systemic Sclerosis test (HAMIS), which is performed by the evaluation of a health professional. The original instrument was designed in English. <h3>Objectives</h3> The aim of this study was to adapt into Spanish the HAMIS test in order to assess hand function in patients with systemic sclerosis and to evaluate its reliability and validity. <h3>Methods</h3> The study included 28 patients that met ACR/EULAR 2013 classification criteria for systemic sclerosis, who attended the Rheumatology Service from March 2014 to March 2015; 21 were diffuse and 7 limited. Patients with overlapping and sclerodermiform syndromes were excluded. Demographic data, clinical manifestations, laboratory studies including ANA by IIF (Hep2) were recorded. Different scores were performed: modified Rodnan, Medsger and Cochin. HAMIS was translated into Spanish and back translated into English. Four translators did not know the original English version of the test. A pilot test was conducted in 5 systemic sclerosis patients and adaptations were performed in order to obtain the final Spanish version. HAMIS test was assessed by an occupational therapist. Two weeks later, the study was repeated in 10 patients chosen randomly to assess stability (test-retest) and concordance according to Bland&amp;Altman. Values of HAMIS and Cochin test were correlated (Spearman9s Rank correlation coefficient). <h3>Results</h3> All 28 patients (27 female) had mean age at diagnosis of 49.6±13 years and median disease duration of 5 years (range=0–25). All patients developed Raynaud9s phenomenon (mean age at onset of Raynaud of 45±17 years), 3 patients had puffy hands, 11 presented digital ulcers, 9 pitting scars and 23 telangiectasia. Through capillaroscopic evaluation, early pattern was found in 11 patients, active in 7 and late in 8 patients. When analyzing severity by Medsger score, such was normal in 1 patient, 11 presented mild involvement, 13 moderate and 3 severe. Median for Rodnan score was of 6 (range=2–27) and 8 for Cochin (range=0–38). Median for HAMIS was of 6 (range=0–21) with Cronbach9s alpha of 0.81; in test-retest: mean of the difference was of 0.091 (range= -5 to +5). Correlation between HAMIS and Cochin was significant (r=0.65; p=0.0002) <h3>Conclusions</h3> An adapted Spanish version of HAMIS was developed, showing an acceptable reliability (Cronbach and stability) and criterion validity (correlation with Cochin test). <h3>Disclosure of Interest</h3> None declared
A Rho-GTPase Effector, Rhotekin-2 (RTKN2) Is Associated with BMP8b and IL-16 Cytokine Expression and Increased Sensitivity to Apoptosis in Lymphocytes.
Authors: Fiona M. Collier, Adele J. Baker, Ken Walder, Nicole Stupka, Sheree D. Martin, Mark A. Kirkland
Journal: Blood (2007)
PTU-050 Addressing The Issue of Indeterminate Interferon Gamma Release Assays Prior to Biologic Therapy in Patients with Inflammatory Bowel Disease Patients
Authors: AA Thi, S Bouri, P Wolfson, L Owen, A Abbara, L John, RN Davidson, AL Hart
Journal: Gut (2016)

<h3>Introduction</h3> Biologic treatment has improved outcomes of patients with complex inflammatory bowel disease (IBD). Anti-TNF therapy is associated with a fivefold increased risk of reactivation of tuberculosis (TB). When TB occurs, it is commonly extra-pulmonary and disseminated with an atypical presentation and can be diagnostically challenging. An indeterminate interferon gamma release assay (IGRA) result occurs in &lt;2% of the healthy population, however this is higher in immunosuppressed patients. Given the increased risk of TB, screening for latent TB infection (LTBI) remains vital before commencing biologics. <h3>Methods</h3> All IBD patients who had an IGRA test between July 2013 and November 2015 before commencing biologic therapy were identified from the high cost funding database held in the Pharmacy Department at St Mark’s Hospital. Clinical and electronic case records were reviewed. <h3>Results</h3> 247 patients were screened for TB with an IGRA test during the study period. The mean age was 36.9 years (range 8–85), 54% were male and 70% had Crohn’s disease. 78 patients (32%) had an indeterminate IGRA result and 35/78 (45%) patients had a repeat test; 17/35 (49%) had a second indeterminate results and the remaining 18 /35 (51%) had a negative test. 8/78 with an indeterminate test had a Mantoux as per our algorithm; 3 were positive, 4 were anergic and 1 was negative. Of the 247 patients, 210 patients received biologic treatment. Thirty-two patients (15%) delayed receiving their biologic treatment for various reasons, including receiving LTBI treatment. Of 210 patients, 158 patients (75%) had Infliximab,38 patients (18%) had Adalimumab, 13 had Vedolizumab and 1 had Golimumab. 30 patients were referred for an infectious diseases opinion; 7 with a positive IGRA and 7 with a negative IGRA but abnormalities on their chest X-ray and a high epidemiological risk for TB. One patient who had an indeterminate IGRA result developed active TB during the study period. <h3>Conclusion</h3> Almost one third of IBD patients had an indeterminate IGRA with half of those having a second indeterminate result. Sampling and processing factors also influence the prevalence of indeterminate results in this population. This supports risk stratification with more weight added to the risk than IGRA alone. Reactivation of LTBI may lead to delays in starting treatment hence it is vital to take into account the patient’s pre-test probability of LTBI before using an IGRA to avoid such delays. <h3>Reference</h3> 1 Wong H, Ip M, Tang W, <i>et al</i>. Performance of the interferon-gamma release assay for Tuberculosis screening in inflammatory Bowel disease patients. <i>IBD</i> 2014;<b>20</b>(11):2067–2072. <h3>Disclosure of Interest</h3> None Declared
Modifiable lifestyle factors associated with risk of sessile serrated polyps, conventional adenomas and hyperplastic polyps
Authors: James R Davenport, Timothy Su, Zhiguo Zhao, Helen G Coleman, Walter E Smalley, Reid M Ness, Wei Zheng, Martha J Shrubsole
Journal: Gut (2016)

Objective To identify modifiable factors associated with sessile serrated polyps (SSPs) and compare the association of these factors with conventional adenomas (ADs) and hyperplastic polyps (HPs). Design We used data from the Tennessee Colorectal Polyp Study, a colonoscopy-based case–control study. Included were 214 SSP cases, 1779 AD cases, 560 HP cases and 3851 polyp-free controls. Results Cigarette smoking was associated with increased risk for all polyps and was stronger for SSPs than for ADs (OR 1.74, 95% CI 1.16 to 2.62, for current vs never, p trend =0.008). Current regular use of non-steroidal anti-inflammatory drugs was associated with a 40% reduction in SSP risk in comparison with never users (OR 0.68, 95% CI 0.48 to 0.96, p trend =0.03), similar to the association with AD. Red meat intake was strongly associated with SSP risk (OR 2.59, 95% CI 1.41 to 4.74 for highest vs lowest intake, p trend &lt;0.001) and the association with SSP was stronger than with AD (p trend =0.003). Obesity, folate intake, fibre intake and fat intake were not associated with SSP risk after adjustment for other factors. Exercise, alcohol use and calcium intake were not associated with risk for SSPs. Conclusions SSPs share some modifiable risk factors for ADs, some of which are more strongly associated with SSPs than ADs. Thus, preventive efforts to reduce risk for ADs may also be applicable to SSPs. Additionally, SSPs have some distinctive risk factors. Future studies should evaluate the preventive strategies for these factors. The findings from this study also contribute to an understanding of the aetiology and biology of SSPs.
Melanoma Prevention—Avoiding Indoor Tanning and Minimizing Overexposure to the Sun
Authors: Jeffrey E. Gershenwald, Allan C. Halpern, Vernon K. Sondak
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0486 Presenting Manifestations of Systemic Lupus Erythematosus in A Cohort of 100 SLE Patients from A Single Center
Authors: M. Sefik Bukilica, N. Terzic Stanic, L. Kovacevic, O. Pajic, N. Vujasinovic Stupar
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a multiorgan disease with protean manifestations and its diagnosis can pose a considerable challenge. <h3>Objectives</h3> The aim of the study was to analyze clinical and laboratory manifestations at the onset of SLE and to compare ACR and the SLICC criteria for the classification of SLE. <h3>Methods</h3> A retrospective study of a well characterized SLE cohort of 100 patients was undertaken. All patients met four or more updated ACR criteria (range 4–8). The following data were collected: age, gender, initial manifestations, time from the first symptom or disorder to definite diagnosis and clinical and laboratory features at the time of SLE diagnosis. <h3>Results</h3> Of the 100 patients analyzed 91 were women, the mean age at the time of diagnosis was 36.56±11.61 years. The most common presenting features were mucocutaneous (77%) and musculoskeletal (76%) manifestations, fatigue (74.6%), fever (52%) and non-scarring alopecia (34%). Median time from the first symptom/disorder to diagnosis was 10 months (range 1–120 months). At diagnosis most of the patients had elevated inflammatory markers ESR and CRP (87.4% and 50% respectively). Anemia and leukopenia was detected in 61% and 48% patients respectively. Serositis was observed in 24%, renal manifestations in 15% and psychosis or seizures in 7% of patients. Positive ANA were present in 97% of patients, anti-dsDNA antibodies in 66%, anti-Sm antibodies in 29.8%, aCL in 18.2%, aB2GPI in 13.8%, LA in 27% and low complement levels in 44.3%. All patients met also SLICC criteria (range 4–11), and significant number of them fulfilled items not contained in updated ACR criteria (non-scaring alopecia, low complement and other neuropsychiatric manifestations). <h3>Conclusions</h3> The prevalence of various clinical and laboratory features associated with SLE in our patients is comparable to findings of most major studies. We have shown that some patients could be diagnosed earlier using SLICC criteria. Furthermore, elevated inflammatory markers support SLE diagnosis. <h3>References</h3> Font J, Cervera R, Ramois-Casals M et al. Clusters of clinical and immunological features in systemic lupus erythematosus. Analysis of 600 patients from a single center. Semin Arthritis Rheum 2004;33:217–30. Bertsias GK, Pamfil C, Fanouriakisd A, Bumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come. Nat Rev Rheumatol 2013;9:687–94. <h3>Disclosure of Interest</h3> None declared
CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation
Authors: Ran Reshef, Austin P. Huffman, Amy Gao, Mary Sell, Marlise R. Luskin, Selina M. Luger, Alison Wakoff Loren, Elizabeth O. Hexner, Sunita Dwivedy Nasta, Noelle V. Frey, Saar I. Gill, James Mangan, Lee P. Richman, Taku Kambayashi, Edward A. Stadtmauer, Robert H. Vonderheide, David L. Porter
Journal: Blood (2014)
AB0022 Modulation of Treg Stability and Function by Inhibition of IL-1beta
Authors: G. Almanzar, M. Greupner, P. Morris, K. Hoefner, N. El Hajj, T. Haaf, M. Schmalzing, J.P. Haas, H.P. Tony, M. Prelog
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> High plasticity was described for Th1 and Th17 cells depending on the local cytokine milieu and regulation by Tregs. Pathogen-induced human Th17 cells and Tregs are strongly regulated by IL-1beta. So far, the influence of IL-1beta on FoxP3 methylation and stability of the Treg lineage has not been investigated. Further, whether inhibition of IL-1beta and its receptor is able to promote FoxP3 demethylation and to conserve Treg functions, such as suppression of Th17 and Th1 functions, has not been assessed in healthy humans, as well as in patients with autoimmune arthritis. <h3>Objectives</h3> Thus, the present study aimed to investigate <i>in vitro</i> nTreg and iTreg functions in lymphocytes obtained from stored routine blood samples of patients with juvenile idiopathic arthritis (JIA) or rheumatoid arthritis (RA) in different disease activity states. <h3>Methods</h3> Proportions of peripheral nTregs and cultured iTregs from stored routine blood samples taken from JIA, RA patients and healthy, age-matched controls (HC) and intracellular cytokine production were analyzed by flow cytometry. Suppressive function of iTregs under <i>in vitro</i> inhibition of IL-1beta was studied by suppression assays. <i>FOXP3</i> expression and methylation were analyzed by quantitative PCR and bisulfite pyrosequencing. <h3>Results</h3> Lower proportions of nTregs were found in samples of JIA patients with acute disease flare (mean 2.3% of CD4+ T cells) compared to HC (4.1%) (p&lt;0.001). Using IL-1beta and other Th17-stimulating cytokines, proportions of induced iTregs were similar between JIA samples with acute disease flare (mean 34.6% of CD4+ T cells) and healthy children (38.1%), but lower in remission (13.2%) (p&lt;0.001). Proportions of iTregs were markedly induced by blockade of IL-1beta in both JIA (mean 78.1% of CD4+ T cells) and HC (84.0%) compared to cells without blockade (p&lt;0.01). IL-1beta blockade reduced proliferation of effector T cells by induction of suppressive function of iTregs in both JIA (suppression from 55.1% to 34.2% proliferating effectors) and HC (from 48.2% to 31.8%) (p&lt;0.001). Intracellular IL-10 production was not influenced by blockade of IL-1beta. <h3>Conclusions</h3> Induction of Tregs seems to be different depending on disease activity status in autoimmune arthritis. DNA methylation at the <i>FOXP3</i> promoter and enhancer regions may influence expression of FoxP3 in Tregs and, thus, modify their phenotype. Although IL-10 was not markedly influenced by IL-1beta-dependent mechanisms, our findings indicate that suppressive iTreg functions may be restored by selective blockade of IL-1beta. <h3>Disclosure of Interest</h3> None declared
Cytokine Induced Killer (CIK) Cells Transduced with an Anti-CD19 Chimeric Receptor Containing 4-1BB Acquire Powerful Anti-Leukemic Activity.
Authors: Virna Marin, Giovanna D’Amico, Harumi Kakuda, Erica Dander, Dario Campana, Andrea Biondi
Journal: Blood (2006)
AB0986 A Systematic Screening of Comorbidities by The Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Authors: A. Tubery, P. Fesler, G. Du Cailar, J. Morel, J. Bousquet, B. Combe, C. Daien
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In chronic inflammatory rheumatic diseases, comorbidities such as cardiovascular disease and infections are sub-optimally managed. EULAR recently developed points to consider to collect and report comorbidities and up-dated recommendation on cardiovascular disease evaluation. <h3>Objectives</h3> We developed a systematic screening of comorbidities in out-patient daily clinic of the Rheumatology department in Montpellier University Hospital. Our objective was to evaluate the impact of such a screening. <h3>Methods</h3> The assessment included rheumatism evaluation, cardiovascular risk factors and diseases, osteoporosis, chronic respiratory disease screenings, check-up of vaccine calendar and recommended neoplasia screenings. This was a medical and paramedics evaluation (physicians, nurses and physiotherapists) including anthropometric and blood pressure measures, blood tests, vessel ultrasound, echocardiography, self-questionnaires, spirometry and bone mineral density. Therapeutic changes for rheumatism and osteoporosis were performed during hospitalization whereas those related to cardiovascular and lung diseases were addressed to the general practitioner. Three months later, patients were called and the application of recommendation evaluated. <h3>Results</h3> 200 patients had a systematic chronic disease screening with 78.5% (n=157) of RA, 18.5% (n=37) of spondyloarthritis, and 3% (n=6) of other diseases. The mean rheumatism duration was 14±9 years, the mean age was 59±11 years. Unknown or uncontrolled hypertension was diagnosed in 20.5% (n=41); LDL above the recommended target in 63% (n=126); unknown diabetes in 3.5% (n=7) of the patients and uncontrolled diabetes in 4 of the diabetic patients (23.5%). Moreover, 7 patients had low systolic pression index (3.5%), 10 had a significant supra-aortic vessel stenosis of more than 50% (5%) and 18 had significant abnormalities in echocardiography (9%). An obstructive respiratory syndrome was found in 20 patients (10%) and sleep apnea syndrome in 78 patients (39%). An anti-osteoporosis drug was prescribed in 11% (n=22) patients. The update of the vaccinations and the neoplasia screenings were proposed for 52.5% (n=105) and 39% (n=79) patients respectively. 144 patients received physiotherapy or occupational therapy advice for the management of their rheumatologic disease (72%). At 3 months, patients declared to have followed the recommendations in 50 to 75% of the cases, the items related to rheumatology being more often applied. <h3>Conclusions</h3> A daily hospitalisation for comorbidities screening seems profitable with many abnormalities discovered in patients yet monitored regularly at hospital. The effective implementation of the proposed or prescribed measures is being assessed. <h3>Disclosure of Interest</h3> None declared
Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma
Authors: Elena Zamagni, Giuseppe Bandini, Annalisa Pezzi, Paola Tacchetti, Ilaria Rizzello, Lucia Pantani, Mario Arpinati, Beatrice A Zannetti, Serena Rocchi, Mariarosaria Sessa, Annamaria Brioli, Katia Mancuso, Carolina Terragna, Nicoletta Testoni, Francesca Bonifazi, Michele Cavo
Journal: Blood (2015)
AB0801 Osteoporosis Frequency and The Association of Rank, Rankl, Osteoprotegerin Gene Polymorphisms with Osteoporosis in Gout Patients
Authors: C.C. Karatay, A. Balkarli, L. Elmas, B. Can, E. Tepeli, V. Cobankara
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is a disease characterized by acute arthritis as a result of increased serum uric acid concentration and deposition of monosodium urate crystals into tissues. In recent times the significant role of RANK- RANKL- OPG network in bone remodeling and osteoclastogenesis was proven. In patients with osteoporosis and in rheumatoid arthritis patients, genetic variations in the genes encoding RANK, RANKL and OPG was investigated and conflicting results were obtained. Also the role of these genes in the pathogenesis of psoriasis, psoriatic arthritis and ankylosing spondylitis has been researched. There is not any study that evaluates RANK, RANKL, Osteoprotegerin gene polymorphisms and their association with the susceptibility to osteoporosis in gout patients. To the best of our knowledge, this is the first study to investigate this subject. <h3>Methods</h3> 69 gout patients, 50 RA patients and 51 healthy controls were recruited for this study. BMD of lumbar spine and femoral sites were measured using DEXA. After acquisition of the BMD T- score, the patients and controls divided into normal, osteopenic and osteoporotic groups according to WHO criteria. We studied 7 SNP in the genes of RANK gene (2 SNP: rs1805034, rs35211496), OPG gene (2 SNP: rs3102735, rs 2073618) and RANKL gene (3 SNP: rs9533156, rs1054016, rs2277438) using real time PCR. <h3>Results</h3> There was no significant difference for BMD scores between three groups. The 7 SNP genotypes showed no significant difference between three groups. The 7 SNP allel frequencies showed no significant difference between three groups. Gout patients with rs1805034 wild genotype had lower incidence of osteoporosis at the femoral sites. Gout patients with rs1805034 heterozygous genotype had higher incidence of normal BMD scores at the femoral sites than other gout patients. Controls with rs2277238 wild genotype, had lower incidence of osteoporosis and those with mutant genotype had higher incidence of osteoporosis at any sites than other controls. Controls with normal BMD at lumbar spine, frequency of rs35211496 wild genotype was higher than other controls. <h3>Conclusions</h3> As a result it is seen that the C allel of the RANK SNP rs1805034 is protective against osteoporosis at femoral site in gout patients. The A allel of the RANKL SNP rs2277438 is protective against osteoporosis at either femoral sites or lumbar spine in healthy people. BMD in patients with Gout, RA and healthy population unexpectedly is not different from each other which may be related to low number of cases. Genotype distribution and genetic diversity varies between ethnic groups. There is a need for more studies with larger patient populations to explain the subject. <h3>Disclosure of Interest</h3> None declared